5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schiz
IPHARMA article "5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)" has been published in the "Journal of Clinical Psychopharmacology".
Treating patients who experience residual psychotic symptoms during remission of schizophrenia remains one of the most challenging problems. The mechanisms underlying these symptoms differ from those of acute hallucinations and delusions. 5-HT6 receptor antagonists have been considered promising agents in treatment of residual psychotic symptoms and cognitive dysfunction. The aim of the study was to assess the efficacy of a selective 5-HT6 inhibitor Avisetron in the reduction of residual psychotic symptoms in patients with schizophrenia on stable antipsychotic therapy.
Eighty clinically stable outpatient subjects with schizophrenia with residual psychotic symptoms were randomized in a double-blind manner to 6 weeks of Avisetron or placebo at 1:1 ratio. Subjects received 8 mg of Avisetron or placebo on top their stable antipsychotic treatment. Standard clinical scales and cognitive tests were used for endpoint assessment. The primary efficacy endpoint was the mean reduction of total Positive and Negative Syndrome Scale score after 6 weeks of treatment.
Vostokova, Natalia, PharmD
Morozova, Margarita MD, PhD
Burminskiy, Denis MD
Rupchev, George PhD
Lepilkina, Taissia MPsych
Potanin, Sergey MD, PhD
Beniashvili, Allan MD, PhD
Lavrovsky, Yan MD, PhD
Ivaschenko, Alexander PhD
*From the Mental Health Research Center, Moscow, Russia; R-Pharm Overseas, Inc, San Diego, CA; IPHARMA LLC (ChemRar/ChemDiv group), Moscow, Russia; ChemDiv, San-Diego, CA.